Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | MC5R | P33032 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25326809 | 0.92 | RORC (0.41) | RORCTACR1NR1H2NR1H3HDAC2 | |
| SCHEMBL25327905 | 0.92 | RORC (0.41) | RORCTACR1NR1H2NR1H3HDAC2 | |
| SCHEMBL30522971 | 0.92 | RORC (0.41) | RORCTACR1NR1H2NR1H3HDAC2 | |
| SCHEMBL25327901 | 0.92 | RORC (0.41) | RORCTACR1NR1H2NR1H3HDAC2 | |
| SCHEMBL25326815 | 0.92 | RORC (0.41) | RORCTACR1NR1H2NR1H3HDAC2 | |
| SCHEMBL30522909 | 0.91 | NR1H2 (0.40) | RORCNR1H2NR1H3GPR119 | |
| SCHEMBL30522994 | 0.88 | RORC (0.35) | RORCTACR1NR1H2NR1H3HDAC2 | |
| SCHEMBL30523072 | 0.87 | TACR1 (0.35) | RORCTACR1NR1H2NR1H3SIGMAR1 | |
| SCHEMBL25326002 | 0.86 | TACR1 (0.41) | RORCTACR1NR1H2NR1H3HDAC2 | |
| SCHEMBL25326005 | 0.86 | TACR1 (0.41) | RORCTACR1NR1H2NR1H3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |